K. Ray

First name
K.
Middle name
K.
Last name
Ray
Ray, K. K., Pillas, D., Hadjiphilippou, S., Khunti, K., Seshasai, S. R. K., Vallejo-Vaz, A. J., et al. (2023). Premature morbidity and mortality associated with potentially undiagnosed familial hypercholesterolemia in the general population. Am J Prev Cardiol, 15, 100580. http://doi.org/10.1016/j.ajpc.2023.100580
View
McKay, A. J., Gunn, L. H., & Ray, K. K. (2022). Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort. Atherosclerosis. http://doi.org/10.1016/j.atherosclerosis.2022.07.011
View
Hageman, S. H. J., McKay, A. J., Ueda, P., Gunn, L. H., Jernberg, T., Hagström, E., et al. (2022). Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. Eur Heart J. http://doi.org/10.1093/eurheartj/ehac056
View
Boggon, R., van Staa, T. P., Timmis, A., Hemingway, H., Ray, K. K., Begg, A., et al. (2011). Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction\textendasha hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J. http://doi.org/10.1093/eurheartj/ehr340
View
Poole, C. D., Halcox, J. P., Jenkins-Jones, S., Carr, E. S., Schifflers, M. G., Ray, K. K., & Currie, C. J. (2013). Omega-3 Fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: a retrospective, matched-cohort study. Clin Ther. http://doi.org/10.1016/j.clinthera.2012.11.008
View
Brownrigg, J. R., Hughes, C. O., Burleigh, D., Karthikesalingam, A., Patterson, B. O., Holt, P. J., et al. (2016). Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol. http://doi.org/10.1016/s2213-8587(16)30057-2
View
Danese, M. D., Gleeson, M., Kutikova, L., Griffiths, R. I., Azough, A., Khunti, K., et al. (2016). Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. BMJ Open. http://doi.org/10.1136/bmjopen-2016-011805
View
Danese, M. D., Gleeson, M., Kutikova, L., Griffiths, R. I., Khunti, K., Seshasai, S. R. K., & Ray, K. K. (2017). Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. BMJ Open. http://doi.org/10.1136/bmjopen-2016-013851
View
Khunti, K., Danese, M. D., Kutikova, L., Catterick, D., Sorio-Vilela, F., Gleeson, M., et al. (2018). Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. JAMA Netw Open. http://doi.org/10.1001/jamanetworkopen.2018.5554
View
McKay, A. J., Gunn, L. H., Ference, B. A., Dorresteijn, J. A. N., Berkelmans, G. F. N., Visseren, F. L. J., & Ray, K. K. (2021). Is the SMART risk prediction model ready for real-world implementation? A validation study in a routine care setting of approximately 380 000 individuals. Eur J Prev Cardiol. http://doi.org/10.1093/eurjpc/zwab093
View